BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qu P, Zhang W, Li D, Zhang C, Liu Q, Zhang X, Wang X, Dai W, Xu Y, Leng Q, Zhong J, Jin X, Huang Z. Insect cell-produced recombinant protein subunit vaccines protect against Zika virus infection. Antiviral Res 2018;154:97-103. [PMID: 29665376 DOI: 10.1016/j.antiviral.2018.04.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Prates JWO, Xisto MF, Rodrigues JVDS, Colombari JPC, Meira JMA, Dias RS, Silva CCD, de Paula ESO. Zika Virus Envelope Protein Domain III Produced in K. phaffii Has the Potential for Diagnostic Applications. Diagnostics 2022;12:1198. [DOI: 10.3390/diagnostics12051198] [Reference Citation Analysis]
2 Hu H, Liu R, Li Q, Wang J, Deng Q, Lu Y, Wu Q, Chen Z, Lu J. Development of a neutralizing antibody targeting linear epitope of the envelope protein domain III of ZIKV. Virus Res 2021;306:198601. [PMID: 34678322 DOI: 10.1016/j.virusres.2021.198601] [Reference Citation Analysis]
3 Yang C, Gong R, de Val N. Development of Neutralizing Antibodies against Zika Virus Based on Its Envelope Protein Structure. Virol Sin 2019;34:168-74. [PMID: 31020573 DOI: 10.1007/s12250-019-00093-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
4 Qu P, Zhang C, Li M, Ma W, Xiong P, Liu Q, Zou G, Lavillette D, Yin F, Jin X, Huang Z. A new class of broadly neutralizing antibodies that target the glycan loop of Zika virus envelope protein. Cell Discov 2020;6:5. [PMID: 32025335 DOI: 10.1038/s41421-019-0140-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
5 Lin HH, Yang SP, Tsai MJ, Lin GC, Wu HC, Wu SC. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization. Theranostics 2019;9:4811-26. [PMID: 31367259 DOI: 10.7150/thno.35919] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
6 Ghaffar KA, Ng LFP, Renia L. Fast Tracks and Roadblocks for Zika Vaccines. Vaccines (Basel) 2018;6:E77. [PMID: 30469444 DOI: 10.3390/vaccines6040077] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Chen MY, Chai KM, Chiang CY, Wu CC, Yu GY, Liu SJ, Chen HW. Recombinant lipidated Zika virus envelope protein domain III elicits durable neutralizing antibody responses against Zika virus in mice. J Biomed Sci 2020;27:51. [PMID: 32290844 DOI: 10.1186/s12929-020-00646-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Luo D, Miao Y, Ke X, Tan Z, Hu C, Li P, Wang T, Zhang Y, Sun J, Liu Y, Wang H, Zheng Z. Baculovirus Surface Display of Zika Virus Envelope Protein Protects against Virus Challenge in Mouse Model. Virol Sin 2020;35:637-50. [PMID: 32472451 DOI: 10.1007/s12250-020-00238-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Chen C, Chen C, Wang W, Lionel V, Liu C, Huang L, Wu S. Intranasal Immunization with Zika Virus Envelope Domain III-Flagellin Fusion Protein Elicits Systemic and Mucosal Immune Responses and Protection against Subcutaneous and Intravaginal Virus Challenges. Pharmaceutics 2022;14:1014. [DOI: 10.3390/pharmaceutics14051014] [Reference Citation Analysis]
10 Zhang W, Qu P, Li D, Zhang C, Liu Q, Zou G, Dupont-Rouzeyrol M, Lavillette D, Jin X, Yin F, Huang Z. Yeast-produced subunit protein vaccine elicits broadly neutralizing antibodies that protect mice against Zika virus lethal infection. Antiviral Res 2019;170:104578. [PMID: 31394119 DOI: 10.1016/j.antiviral.2019.104578] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
11 Liu R, Ma H, Shu J, Zhang Q, Han M, Liu Z, Jin X, Zhang F, Wu X. Vaccines and Therapeutics Against Hantaviruses. Front Microbiol 2019;10:2989. [PMID: 32082263 DOI: 10.3389/fmicb.2019.02989] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
12 Benazzato C, Russo FB, Beltrão-Braga PCB. An update on preclinical pregnancy models of Zika virus infection for drug and vaccine discovery. Expert Opin Drug Discov 2021;:1-7. [PMID: 34461793 DOI: 10.1080/17460441.2021.1973999] [Reference Citation Analysis]
13 Joshi A, Ray NM, Singh J, Upadhyay AK, Kaushik V. T-cell epitope-based vaccine designing against Orthohantavirus: a causative agent of deadly cardio-pulmonary disease. Netw Model Anal Health Inform Bioinform 2022;11:2. [PMID: 34900515 DOI: 10.1007/s13721-021-00339-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Yang C, Zeng F, Gao X, Zhao S, Li X, Liu S, Li N, Deng C, Zhang B, Gong R. Characterization of two engineered dimeric Zika virus envelope proteins as immunogens for neutralizing antibody selection and vaccine design. J Biol Chem 2019;294:10638-48. [PMID: 31138647 DOI: 10.1074/jbc.RA119.007443] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
15 Zhou Y, Chen D, Yang L, Zou W, Duan Z, Zhang Y, Wen J. Dengue virus envelope protein domain III-elicited antibodies mediate cross-protection against Zika virus in a mouse model. Virus Research 2020;278:197882. [DOI: 10.1016/j.virusres.2020.197882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Yang R, Liu Q, Pang W, Gao F, Liang H, Zhang W, Lin Y, Li M, Liu Z, Gao GF, Zhang L, Xiao H, Zheng Y, Huang Z, Jin X. Two immunogenic recombinant protein vaccine candidates showed disparate protective efficacy against Zika virus infection in rhesus macaques. Vaccine 2021;39:915-25. [PMID: 33451779 DOI: 10.1016/j.vaccine.2020.12.077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Saiz JC. Therapeutic Advances Against ZIKV: A Quick Response, a Long Way to Go. Pharmaceuticals (Basel) 2019;12:E127. [PMID: 31480297 DOI: 10.3390/ph12030127] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Metz SW, Thomas A, Brackbill A, Forsberg J, Miley MJ, Lopez CA, Lazear HM, Tian S, de Silva AM. Oligomeric state of the ZIKV E protein defines protective immune responses. Nat Commun 2019;10:4606. [PMID: 31601808 DOI: 10.1038/s41467-019-12677-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
19 Abernathy ME, Dam KA, Esswein SR, Jette CA, Bjorkman PJ. How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika. Viruses 2021;13:2106. [PMID: 34696536 DOI: 10.3390/v13102106] [Reference Citation Analysis]
20 Garg H, Mehmetoglu-Gurbuz T, Joshi A. Recent Advances in Zika Virus Vaccines. Viruses 2018;10:E631. [PMID: 30441757 DOI: 10.3390/v10110631] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]